Maurice Pérol, M.D., is a leading thoracic oncologist with extensive experience in clinical research and lung cancer treatment. He served as Head of the Department of Thoracic Oncology at Croix-Rousse University Hospital in Lyon from 1993 to 2011 and currently leads the Thoracic Oncology Program at the Léon Bérard Cancer Centre.

 

Dr. Pérol has been principal or key investigator in numerous national and international clinical trials across all phases (I–III). He is an active member of major scientific societies, including ASCO, ESMO, IASLC, and cooperative research groups.

 

His leadership roles include Chair of the Groupe Français de Pneumo-Cancérologie (GFPC) and Board Member of the Intergroupe Francophone de Cancérologie Thoracique (IFCT). He currently serves on the Scientific Council of the European Thoracic Oncology Platform (ETOP). Dr. Pérol has authored or co-authored over 300 peer-reviewed publications.

Dr Maurice Pérol has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AnHeart Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Gritstone, Ipsen, Janssen, Merck Sharp & Dohme, Novartis, Novocure, Nuvation Bio, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Takeda